C Criscitiello
Overview
Explore the profile of C Criscitiello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
2406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boscolo Bielo L, Guerini Rocco E, Trapani D, Zagami P, Taurelli Salimbeni B, Esposito A, et al.
ESMO Open
. 2024 Oct;
9(10):103731.
PMID: 39357123
Background: Somatic genetic alterations of the estrogen receptor 1 gene (ESR1) are enriched in endocrine therapy-resistant, estrogen receptor-positive (ER+) metastatic breast cancer (mBC). Herein, we investigated and compared the clinical...
2.
Morganti S, Bianchini G, Giordano A, Giuliano M, Curigliano G, Criscitiello C
ESMO Open
. 2022 Mar;
7(2):100428.
PMID: 35272131
Since its first approval in 2006, 1 year of adjuvant trastuzumab has been the standard of care for early-stage HER2-positive breast cancer. Nevertheless, the optimal duration of adjuvant trastuzumab was...
3.
Trapani D, Giugliano F, Uliano J, Zia V, Marra A, Viale G, et al.
Breast Cancer Res Treat
. 2021 May;
187(2):323-337.
PMID: 34043122
Purpose: Breast cancer (BC) is a leading cause of morbidity, disability, and mortality in women, worldwide; triple-negative BC (TNBC) is a subtype traditionally associated with poorer prognosis. TNBC special histology...
4.
Trapani D, Gandini S, Corti C, Crimini E, Bellerba F, Minchella I, et al.
Cancer Treat Rev
. 2021 Apr;
97:102205.
PMID: 33878560
The role of adjuvant chemotherapy (aCT) for patients with localized lobular breast cancer (ILC) is still controversial. It is unclear what is the magnitude of benefit of the CT in...
5.
MORGAN G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, et al.
ESMO Open
. 2021 Apr;
6(2):100104.
PMID: 33838532
Background: The COVID-19 pandemic has impacted all aspects of modern-day oncology, including how stakeholders communicate through social media. We surveyed oncology stakeholders in order to assess their attitudes pertaining to...
6.
7.
Criscitiello C, Vingiani A, Maisonneuve P, Viale G, Curigliano G
Breast Cancer Res Treat
. 2020 Jul;
183(2):347-354.
PMID: 32621251
Purpose: The prognostic role of tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer (BC) is debated. We evaluated the association of TILs and clinico-pathological features with distant disease-free survival (DDFS) in...
8.
Park J, Jonas S, Bataillon G, Criscitiello C, Salgado R, Loi S, et al.
Ann Oncol
. 2019 Oct;
30(12):1941-1949.
PMID: 31566659
Background: Although stromal tumor-infiltrating lymphocytes (sTILs) have been considered an important prognostic factor in early-stage triple-negative breast cancer (TNBC), there have been limited data on their prognostic value in the...
9.
Malorni L, Curigliano G, Minisini A, Cinieri S, Tondini C, DHollander K, et al.
Ann Oncol
. 2018 Jun;
29(8):1748-1754.
PMID: 29893790
Background: The activity of palbociclib as a single agent in advanced breast cancer has not been extensively studied, with the only available clinical data limited to heavily pretreated patients. Preclinical...
10.
Di Cosimo S, Campbell C, Azim Jr H, Galli G, Bregni G, Curigliano G, et al.
Eur J Cancer
. 2017 Dec;
89:42-48.
PMID: 29227816
Aim: To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial. Patients And Methods: Mammography and US...